Literature DB >> 16210911

RNA interference remarkably suppresses bcl-2 gene expression in cancer cells in vitro and in vivo.

Geng-Feng Fu1, Xue-Hong Lin, Qing-Wang Han, Yan-Rong Fan, Ye-Fen Xu, Dan Guo, Gen-Xing Xu, Ya-Yi Hou.   

Abstract

Bcl-2 is an anti-apoptotic protein. If the level of Bcl-2 protein can be reduced sufficiently in tumors using RNA interference (RNAi) to target the gene message, the apoptosis of tumor cells may be promoted. In this study, we synthesized 19 nucleotides (nts) small interference RNA (siRNA) constructs suppressing bcl-2 gene expression in human tumor cells (HeLaB2 and BGC-823 cell lines) in vitro. The bcl-2 gene expression levels were significantly reduced when these siRNA were transfected into experimental two tumor cells for 72 hours. The apoptosis process was also examined in the tumor cells. Here we synthesized siRNA from a DNA template under the control of the RNA polymerase III promoter in transfected tumor cells. Using this DNA vector-based approach, we found that the siRNA efficiently and specifically inhibited the synthesis of protein encoded by the bcl-2 gene in HeLaB2 and BGC-823 tumor cells. Tumor growth was inhibited by 66.5% with 2mg/kg pSilencer 3.1H1-bcl-2 in mouse liver tumor-bearing BALB/c mice. This approach may prove to be a valuable clinical technique for the analysis of specific gene functions and gene therapy of malignant tumors that utilize the bcl-2 gene via RNA interference.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16210911     DOI: 10.4161/cbt.4.8.1889

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  9 in total

1.  Asymmetric siRNA: new strategy to improve specificity and reduce off-target gene expression.

Authors:  Zhongping Yuan; Xilin Wu; Chao Liu; Genxing Xu; Zhiwei Wu
Journal:  Hum Gene Ther       Date:  2012-03-09       Impact factor: 5.695

2.  Galangin induces apoptosis of hepatocellular carcinoma cells via the mitochondrial pathway.

Authors:  Hai-Tao Zhang; Hui Luo; Jun Wu; Liu-Bo Lan; Da-Hua Fan; Kai-Dan Zhu; Xiao-Yi Chen; Min Wen; Hui-Ming Liu
Journal:  World J Gastroenterol       Date:  2010-07-21       Impact factor: 5.742

3.  Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint.

Authors:  Xiaoming Ju; Mathew C Casimiro; Michael Gormley; Hui Meng; Xuanmao Jiao; Sanjay Katiyar; Marco Crosariol; Ke Chen; Min Wang; Andrew A Quong; Michael P Lisanti; Adam Ertel; Richard G Pestell
Journal:  Cancer Res       Date:  2013-11-26       Impact factor: 12.701

4.  Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization.

Authors:  Nelly Buron; Mathieu Porceddu; Magali Brabant; Diana Desgué; Cindy Racoeur; Myriam Lassalle; Christine Péchoux; Pierre Rustin; Etienne Jacotot; Annie Borgne-Sanchez
Journal:  PLoS One       Date:  2010-03-31       Impact factor: 3.240

Review 5.  Gene discovery in cervical cancer : towards diagnostic and therapeutic biomarkers.

Authors:  Cara M Martin; Louise Kehoe; Cathy O Spillane; John J O'Leary
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

6.  The polyamidoamine-mediated inhibition of bcl-2 by small hairpin RNA to induce apoptosis in human lens epithelial cells.

Authors:  Xin-Hua Wu; Yi Lu; Yan-Wen Fang; Yong-Xiang Jiang
Journal:  Mol Vis       Date:  2012-01-12       Impact factor: 2.367

7.  New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids.

Authors:  O A Patutina; N L Mironova; V V Vlassov; M A Zenkova
Journal:  Acta Naturae       Date:  2009-07       Impact factor: 1.845

Review 8.  Progress in gene therapy using oncolytic vaccinia virus as vectors.

Authors:  Xue Yang; Biao Huang; Lili Deng; Zhigang Hu
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-06       Impact factor: 4.322

Review 9.  Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers.

Authors:  Md Emranul Karim; Kyi Kyi Tha; Iekhsan Othman; Mohammad Borhan Uddin; Ezharul Hoque Chowdhury
Journal:  Pharmaceutics       Date:  2018-05-26       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.